Insurance typically covers GLP-1 medications prescribed for eligible conditions such as type 2 diabetes, obstructive sleep apnea, cardiac disease, vascular disease, kidney disease and stroke risk
The segment is expected to exceed USD 3.8 billion by 2035, growing at a CAGR of 14.8% during the forecast period
it demands a nuanced understanding of potency, indication, and titration to avoid adverse effects and ensure therapeutic success
sin embargo, to dava se requieren ms estudios para confirmar su utilidad y costo/efectividad en la prctica clnica 14
Second is the formation of unknown byproducts
Liraglutide 3 mg (Saxenda) : A once-daily GLP-1 receptor agonist injection